This clinical trial is focused on studying a type of cancer called HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. This is a form of cancer that affects the stomach or the area where the stomach meets the esophagus. The study is investigating the effectiveness of a treatment combination that includes the drug pembrolizumab, also known by its code name MK-3475, along with trastuzumab and chemotherapy. Chemotherapy involves using drugs to kill cancer cells or stop them from growing. The study also includes a comparison with a placebo, which is a substance with no active medication.

The purpose of the study is to compare how well patients do with the different treatment combinations. Participants will receive either the combination of pembrolizumab, trastuzumab, and chemotherapy or trastuzumab, chemotherapy, and a placebo. The study will monitor how long patients live without the cancer getting worse and their overall survival. The treatment will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. Some of the chemotherapy drugs used in this study include oxaliplatin, capecitabine, cisplatin, and fluorouracil.

Participants in the study will be closely monitored for any side effects or adverse events, which are any unwanted effects of the treatment. The study aims to provide valuable information on the effectiveness and safety of the treatment combinations for patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The study is expected to last for a period of time, during which participants will receive regular assessments to track their progress and response to the treatment.